{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:34:18Z","timestamp":1794411258032,"version":"4.9.0"},"reference-count":118,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Alexion, AstraZeneca Rare Disease as part of an alliance between AstraZeneca and Merck Sharp"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurofibromatosis type 1 (NF1) is a multisystem genetic condition. Up to 50% of individuals with NF1 develop plexiform neurofibromas (PN) that can cause pain and significant morbidity, impairing quality of life. As of December 2025, only a limited number of countries have an approved medical treatment for adults with NF1-PN. A systematic literature review (PROSPERO CRD42023463980) was conducted to better understand disease burden and unmet need in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An evidence prioritization strategy identified studies reporting on NF1-PN populations with \u226550% adults from database searches conducted between 1988 and July 20, 2023. Studies published in the last 15 years were extracted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 3242 identified sources, 57 publications (53 unique studies) were included. The proportion of adults with NF1 who had PN ranged from 11.8% to 84.9% (n\u2009=\u20099 studies). Annual median change in untreated PN volume was \u22123.7% to +8.3% (n\u2009=\u20095 articles). Pain was the most common PN-related manifestation (32.0%\u201338.4% of patients; n\u2009=\u200912 articles). Malignant PN transformation occurred in 2.0%\u20134.1% of patients (n\u2009=\u20095 cohorts); 3 shorter-term studies reported no transformation. Surgery was performed in 69.5% of patients (n\u2009=\u20097 cohorts); post-operative complications occurred in 13.0%\u201330.0% (n\u2009=\u20093 articles). Analgesia was the most reported pharmacological treatment (37.9% of patients; n\u2009=\u20097 articles). Limited data indicated that PN monitoring and surgery cause substantial resource use. No studies reported on caregiver burden, healthcare costs, or transition from pediatric to adult care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adults with NF1-PN experience high disease burden. Data gaps exist for epidemiology, transition of care, caregiver burden, healthcare cost, and resource use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdaf269","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:30:02Z","timestamp":1768307402000},"source":"Crossref","is-referenced-by-count":3,"title":["Disease burden and unmet needs in adults with neurofibromatosis type 1 and plexiform neurofibromas: A systematic literature review"],"prefix":"10.1093","volume":"8","author":[{"given":"Maciej","family":"Mrugala","sequence":"first","affiliation":[{"name":"Department of Neurology, Medicine and Neurosurgery, Mayo Clinic Cancer Center , Phoenix, Arizona (M.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6987-027X","authenticated-orcid":false,"given":"Ayo","family":"Adeyemi","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease , Boston, Massachusetts (A.A.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Johns","sequence":"additional","affiliation":[{"name":"Costello Medical , London (J.J.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc , Rahway, New Jersey (X.Y.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology (CERENEF), Henri-Mondor Hospital, APHP, UPEC , Cr\u00e9teil,","place":["France"]},{"name":"INSERM CIC 1430 , Cr\u00e9teil, (P.W.)","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"2026042204272754300_vdaf269-B1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s13023-022-02493-5","article-title":"Development of algorithms to identify individuals with neurofibromatosis type 1 within administrative data and electronic medical records in Ontario, Canada","volume":"17","author":"Barnett","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026042204272754300_vdaf269-B2","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/gim.2017.215","article-title":"Prevalence of neurofibromatosis type 1 in the Finnish population","volume":"20","author":"Kallionp\u00e4\u00e4","year":"2018","journal-title":"Genet Med"},{"key":"2026042204272754300_vdaf269-B3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol"},{"key":"2026042204272754300_vdaf269-B4","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"2026042204272754300_vdaf269-B5","doi-asserted-by":"crossref","first-page":"5873","DOI":"10.18632\/oncotarget.2194","article-title":"The NF1 gene revisited\u2014from bench to bedside","volume":"5","author":"Yap","year":"2014","journal-title":"Oncotarget"},{"key":"2026042204272754300_vdaf269-B6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13023-020-1310-3","article-title":"Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966","volume":"15","author":"Bergqvist","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"2026042204272754300_vdaf269-B7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of neurofibromatosis 1 in German children at elementary school enrollment","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch Dermatol"},{"key":"2026042204272754300_vdaf269-B9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmg.37.8.632","article-title":"Epidemiology of neurofibromatosis type 1 (NF1) in northern Finland","volume":"37","author":"Poyhonen","year":"2000","journal-title":"J Med Genet"},{"key":"2026042204272754300_vdaf269-B10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/jmg.2006.045906","article-title":"Guidelines for the diagnosis and management of individuals with neurofibromatosis 1","volume":"44","author":"Ferner","year":"2007","journal-title":"J Med Genet"},{"key":"2026042204272754300_vdaf269-B11","volume-title":"GeneReviews\u00ae","author":"Friedman","year":"1993"},{"key":"2026042204272754300_vdaf269-B12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","article-title":"Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life","volume":"167a","author":"Wolters","year":"2015","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B13","first-page":"55","article-title":"Natural history and disease burden of neurofibromatosis type 1 with plexiform neurofibromas: a systematic literature review","volume":"12","author":"Copley-Merriman","year":"2021","journal-title":"Adolesc Health Med Ther"},{"key":"2026042204272754300_vdaf269-B14","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/neuonc\/noy067","article-title":"Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1","volume":"20","author":"Gross","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026042204272754300_vdaf269-B15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"2026042204272754300_vdaf269-B16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10897-015-9829-5","article-title":"The impact of neurofibromatosis type 1 on the health and wellbeing of Australian adults","volume":"24","author":"Crawford","year":"2015","journal-title":"J Genet Couns"},{"key":"2026042204272754300_vdaf269-B17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/ajmg.a.35840","article-title":"Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge","volume":"161A","author":"Oates","year":"2013","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ajmg.a.61069","article-title":"Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis type 1","volume":"179","author":"Kongkriangkai","year":"2019","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B19","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/ajmg.a.35550","article-title":"Increased risk of breast cancer in women with NF1","volume":"158A","author":"Madanikia","year":"2012","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B20","doi-asserted-by":"crossref","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026042204272754300_vdaf269-B21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1542\/peds.2007-3204","article-title":"Neurofibromatosis type 1 revisited","volume":"123","author":"Williams","year":"2009","journal-title":"Pediatrics"},{"key":"2026042204272754300_vdaf269-B22","doi-asserted-by":"crossref","first-page":"101818","DOI":"10.1016\/j.eclinm.2022.101818","article-title":"ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1","volume":"56","author":"Carton","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026042204272754300_vdaf269-B23","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026042204272754300_vdaf269-B24","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/neuonc\/noaa053","article-title":"Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions","volume":"22","author":"Akshintala","year":"2020","journal-title":"Neuro Oncol"},{"key":"2026042204272754300_vdaf269-B25","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026042204272754300_vdaf269-B26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/gim.2018.28","article-title":"Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"20","author":"Stewart","year":"2018","journal-title":"Genet Med"},{"key":"2026042204272754300_vdaf269-B27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/ajmg.a.38680","article-title":"Worries and needs of adults and parents of adults with neurofibromatosis type 1","volume":"176","author":"Rietman","year":"2018","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B28","first-page":"2207","article-title":"Size of tooth crowns and position of teeth concerning the extension of facial plexiform neurofibroma in patients with neurofibromatosis type 1","volume":"32","author":"Friedrich","year":"2012","journal-title":"Anticancer Res"},{"key":"2026042204272754300_vdaf269-B29","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.21873\/anticanres.15739","article-title":"Posterior-anterior cephalometric study of neurofibromatosis type 1 patients with facial plexiform neurofibroma: analysis of skeletal symmetry concerning midfacial and skull base reference points (zygomatic arch, mastoid, and juga)","volume":"42","author":"Friedrich","year":"2022","journal-title":"Anticancer Res"},{"key":"2026042204272754300_vdaf269-B30","doi-asserted-by":"crossref","first-page":"e065340","DOI":"10.1136\/bmjopen-2022-065340","article-title":"Cohort profile: life with neurofibromatosis 1\u2014the Danish NF1 cohort","volume":"12","author":"Doser","year":"2022","journal-title":"BMJ Open"},{"key":"2026042204272754300_vdaf269-B31","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archderm.137.11.1421","article-title":"Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases","volume":"137","author":"Wolkenstein","year":"2001","journal-title":"Arch Dermatol"},{"key":"2026042204272754300_vdaf269-B32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13023-022-02356-z","article-title":"Transition to adult care of young patients with neurofibromatosis type 1 and cognitive deficits: a single-centre study","volume":"17","author":"Lausdahl","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026042204272754300_vdaf269-B33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/PHMT.S362679","article-title":"Neurofibromatosis type 1 (NF1): addressing the transition from pediatric to adult care","volume":"14","author":"Radtke","year":"2023","journal-title":"Pediatric Health Med Ther"},{"key":"2026042204272754300_vdaf269-B34","author":"European Medicines Agency","year":"2021"},{"key":"2026042204272754300_vdaf269-B35","author":"AstraZeneca Pharmaceuticals LP","year":"2020"},{"key":"2026042204272754300_vdaf269-B36","author":"AstraZeneca","year":"2022"},{"key":"2026042204272754300_vdaf269-B37","author":"AstraZeneca","year":"2023"},{"key":"2026042204272754300_vdaf269-B38","author":"US Food and Drug Administration","year":"2025"},{"key":"2026042204272754300_vdaf269-B39","author":"SpringWorks Therapeutics","year":"2025"},{"key":"2026042204272754300_vdaf269-B40","author":"AstraZeneca","year":"2025"},{"key":"2026042204272754300_vdaf269-B41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/0253-7184.69003","article-title":"Formulating a researchable question: a critical step for facilitating good clinical research","volume":"31","author":"Aslam","year":"2010","journal-title":"Indian J Sex Transm Dis AIDS"},{"key":"2026042204272754300_vdaf269-B42","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2026042204272754300_vdaf269-B43","first-page":"172","article-title":"National Institutes of Health consensus development conference statement: neurofibromatosis. Bethesda, MD, USA, July 13\u201315, 1987","volume":"1","author":"NIH","year":"1988","journal-title":"Neurofibromatosis"},{"key":"2026042204272754300_vdaf269-B44","volume-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Healthcare","author":"Centre for Reviews and Dissemination","year":"2009"},{"key":"2026042204272754300_vdaf269-B45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"2026042204272754300_vdaf269-B46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13052-018-0483-z","article-title":"Clinical and molecular characterization of 112 single-center patients with neurofibromatosis type 1","volume":"44","author":"Corsello","year":"2018","journal-title":"Ital J Pediatr"},{"key":"2026042204272754300_vdaf269-B47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40487-022-00213-4","article-title":"Clinical characteristics and management of children and adults with neurofibromatosis type 1 and plexiform neurofibromas in Denmark: a nationwide study","volume":"11","author":"Ejerskov","year":"2023","journal-title":"Oncol Ther"},{"key":"2026042204272754300_vdaf269-B48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00256-016-2522-4","article-title":"Tumor segmentation of whole-body magnetic resonance imaging in neurofibromatosis type 1 patients: tumor burden correlates","volume":"46","author":"Heffler","year":"2017","journal-title":"Skeletal Radiol"},{"key":"2026042204272754300_vdaf269-B49","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/ajmg.a.37068","article-title":"Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1","volume":"167","author":"Jett","year":"2015","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13023-023-02766-7","article-title":"Blunted circadian variation of blood pressure in individuals with neurofibromatosis type 1","volume":"18","author":"Rivera","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026042204272754300_vdaf269-B51","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/hmg\/ddp212","article-title":"Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1","volume":"18","author":"Sabbagh","year":"2009","journal-title":"Hum Mol Genet"},{"key":"2026042204272754300_vdaf269-B52","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1038\/jid.2010.100","article-title":"NF-1Score: a prediction score for internal neurofibromas in neurofibromatosis-1","volume":"130","author":"Sbidian","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2026042204272754300_vdaf269-B53","doi-asserted-by":"crossref","first-page":"e136262","DOI":"10.1172\/jci.insight.136262","article-title":"Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry","volume":"5","author":"Tabata","year":"2020","journal-title":"JCI Insight"},{"key":"2026042204272754300_vdaf269-B54","doi-asserted-by":"crossref","first-page":"e1009517","DOI":"10.1371\/journal.pgen.1009517","article-title":"Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth","volume":"17","author":"Well","year":"2021","journal-title":"PLoS Genet"},{"key":"2026042204272754300_vdaf269-B55","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-7364-6-12","article-title":"Genotype-phenotype associations in neurofibromatosis type 1 (NF1): an increased risk of tumor complications in patients with NF1 splice-site mutations?","volume":"6","author":"Alkindy","year":"2012","journal-title":"Hum Genomics"},{"key":"2026042204272754300_vdaf269-B56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1172-6-18","article-title":"Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980\u20132006 in France","volume":"6","author":"Duong","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"2026042204272754300_vdaf269-B57","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/annonc\/mdm450","article-title":"[18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study","volume":"19","author":"Ferner","year":"2008","journal-title":"Ann Oncol"},{"key":"2026042204272754300_vdaf269-B58","doi-asserted-by":"crossref","first-page":"ii75","DOI":"10.1093\/neuonc\/noac174.263","article-title":"P11.74. A plexiform neurofibromas prevalence and treatment modalities in a referral comprehensive cancer center","volume":"24","author":"Ferreira","year":"2022","journal-title":"Neuro Oncol."},{"key":"2026042204272754300_vdaf269-B59","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1440-1789.2011.01276.x","article-title":"Hyaluronan in intra-operative edema of NF1-associated neurofibromas","volume":"32","author":"Hagel","year":"2012","journal-title":"Neuropathology"},{"key":"2026042204272754300_vdaf269-B60","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1097\/MPH.0000000000001156","article-title":"Malignant peripheral nerve sheath tumors in neurofibromatosis: impact of family history","volume":"40","author":"Malbari","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"2026042204272754300_vdaf269-B61","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2478\/ahp-2020-0019","article-title":"No significant risk of hematological malignancy in patients with neurofibromatosis type 1: single center study of children and adults","volume":"51","author":"Marja\u0144ska","year":"2020","journal-title":"Acta Haematol Pol"},{"key":"2026042204272754300_vdaf269-B62","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/pbc.24212","article-title":"18-Fluorodeoxyglucose-positron emission tomography (FDG-PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)","volume":"60","author":"Meany","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"2026042204272754300_vdaf269-B63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13072-020-00380-6","article-title":"Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK\/p38 signaling","volume":"14","author":"Grit","year":"2021","journal-title":"Epigenetics Chromatin"},{"key":"2026042204272754300_vdaf269-B64","doi-asserted-by":"crossref","first-page":"e0151809","DOI":"10.1371\/journal.pone.0151809","article-title":"Metabolic tumour burden measured by 18F-FDG PET\/CT predicts malignant transformation in patients with neurofibromatosis type-1","volume":"11","author":"Van Der Gucht","year":"2016","journal-title":"PLoS One"},{"key":"2026042204272754300_vdaf269-B65","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/papr.12695","article-title":"The relationship between heart rate variability, psychological flexibility, and pain in neurofibromatosis type 1","volume":"18","author":"Allen","year":"2018","journal-title":"Pain Pract"},{"key":"2026042204272754300_vdaf269-B66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat Med"},{"key":"2026042204272754300_vdaf269-B67","first-page":"Doc05","article-title":"Sella turcica measurements on lateral cephalograms of patients with neurofibromatosis type 1","volume":"6","author":"Friedrich","year":"2017","journal-title":"GMS Interdiscip Plast Reconstr Surg DGPW"},{"key":"2026042204272754300_vdaf269-B68","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10006-023-01155-5","article-title":"Neurofibromatosis type 1-associated plexiform neurofibromas of the neck: topography of lesions and surgical treatment data of 69 patients","volume":"28","author":"Friedrich","year":"2024","journal-title":"Oral Maxillofac Surg"},{"key":"2026042204272754300_vdaf269-B69","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.jcms.2018.04.018","article-title":"A combination of skeletal deformations of the dorsal mandible and temporomandibular region detected in orthopantomograms of patients with neurofibromatosis type 1 indicates an associated ipsilateral plexiform neurofibroma","volume":"46","author":"Friedrich","year":"2018","journal-title":"J Craniomaxillofac Surg"},{"key":"2026042204272754300_vdaf269-B70","doi-asserted-by":"crossref","first-page":"349","DOI":"10.21873\/invivo.12266","article-title":"Sphenoid bone pneumatisation on lateral cephalograms of patients with neurofibromatosis type 1","volume":"35","author":"Friedrich","year":"2021","journal-title":"In Vivo"},{"key":"2026042204272754300_vdaf269-B71","doi-asserted-by":"crossref","first-page":"889","DOI":"10.21873\/invivo.12329","article-title":"Surgery for peripheral nerve sheath tumours of the buttocks, legs and feet in 90 patients with neurofibromatosis type 1","volume":"35","author":"Friedrich","year":"2021","journal-title":"In Vivo"},{"key":"2026042204272754300_vdaf269-B72","doi-asserted-by":"crossref","first-page":"2050312119829680","DOI":"10.1177\/2050312119829680","article-title":"A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1","volume":"7","author":"Heaney","year":"2019","journal-title":"SAGE Open Med"},{"key":"2026042204272754300_vdaf269-B73","doi-asserted-by":"crossref","first-page":"e1530","DOI":"10.1002\/mgg3.1530","article-title":"The development of the PlexiQoL: a patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas","volume":"8","author":"Heaney","year":"2020","journal-title":"Mol Genet Genomic Med"},{"key":"2026042204272754300_vdaf269-B74","doi-asserted-by":"crossref","first-page":"17857","DOI":"10.1038\/s41598-020-74920-1","article-title":"Image segmentation of plexiform neurofibromas from a deep neural network using multiple b-value diffusion data","volume":"10","author":"Ho","year":"2020","journal-title":"Sci Rep"},{"key":"2026042204272754300_vdaf269-B75","author":"ClinicalTrials.gov","year":"2022"},{"key":"2026042204272754300_vdaf269-B76","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/gim.2013.30","article-title":"Growth behavior of plexiform neurofibromas after surgery","volume":"15","author":"Nguyen","year":"2013","journal-title":"Genet Med"},{"key":"2026042204272754300_vdaf269-B77","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4103\/wjnm.WJNM_71_17","article-title":"Comparison of hybrid 18F. fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging and positron emission tomography\/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1","volume":"17","author":"Raad","year":"2018","journal-title":"World J Nucl Med"},{"key":"2026042204272754300_vdaf269-B78","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-018-4227-5","article-title":"Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET\/MRI","volume":"46","author":"Reinert","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026042204272754300_vdaf269-B79","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ajmg.a.62544","article-title":"Adolescents and young adults with neurofibromatosis type 1: a descriptive study of adaptive functioning","volume":"188","author":"Struemph","year":"2022","journal-title":"Am J Med Genet A"},{"key":"2026042204272754300_vdaf269-B80","doi-asserted-by":"crossref","first-page":"e1003734","DOI":"10.1371\/journal.pmed.1003734","article-title":"Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: a cross-sectional study","volume":"18","author":"Szymanski","year":"2021","journal-title":"PLoS Med"},{"key":"2026042204272754300_vdaf269-B81","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026042204272754300_vdaf269-B82","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jid.2018.09.016","article-title":"Absence of efficacy of everolimus in neurofibromatosis 1-related plexiform neurofibromas: results from a phase 2a trial","volume":"139","author":"Zehou","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2026042204272754300_vdaf269-B83","author":"ClinicalTrials.gov","year":"2023"},{"key":"2026042204272754300_vdaf269-B84","first-page":"e107","article-title":"Decayed, missing, and restored teeth in patients with neurofibromatosis type 1","volume":"10","author":"Friedrich","year":"2018","journal-title":"J Clin Exp Dent"},{"key":"2026042204272754300_vdaf269-B85","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Robertson","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026042204272754300_vdaf269-B86","author":"ClinicalTrials.gov","year":"2017"},{"key":"2026042204272754300_vdaf269-B87","author":"ClinicalTrials.gov","year":"2017"},{"key":"2026042204272754300_vdaf269-B88","first-page":"3180","article-title":"Increased serum concentrations of estrogen-induced growth factors midkine and FGF2 in NF1 patients with plexiform neurofibroma","volume":"14","author":"Atallah","year":"2022","journal-title":"Am J Transl Res"},{"key":"2026042204272754300_vdaf269-B89","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jcms.2017.02.011","article-title":"A lateral cephalometry study of patients with neurofibromatosis type 1","volume":"45","author":"Friedrich","year":"2017","journal-title":"J Craniomaxillofac Surg"},{"key":"2026042204272754300_vdaf269-B90","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/PRS.0b013e3181d180e9","article-title":"Facial aesthetic unit remodeling procedure for neurofibromatosis type 1 hemifacial hypertrophy: report on 33 consecutive adult patients","volume":"125","author":"Hivelin","year":"2010","journal-title":"Plast Reconstr Surg"},{"key":"2026042204272754300_vdaf269-B91","doi-asserted-by":"crossref","first-page":"e0232031","DOI":"10.1371\/journal.pone.0232031","article-title":"The effect of pregnancy on growth-dynamics of neurofibromas in neurofibromatosis type 1","volume":"15","author":"Well","year":"2020","journal-title":"PLoS One"},{"key":"2026042204272754300_vdaf269-B92","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.wneu.2017.09.066","article-title":"Clinical value of multiparametric whole-body magnetic resonance imaging over whole-spine magnetic resonance imaging in patients with neurofibromatosis type I","volume":"108","author":"Zhang","year":"2017","journal-title":"World Neurosurg"},{"key":"2026042204272754300_vdaf269-B93","doi-asserted-by":"crossref","first-page":"e2521","DOI":"10.1212\/WNL.0000000000009490","article-title":"Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics","volume":"94","author":"Liu","year":"2020","journal-title":"Neurology"},{"key":"2026042204272754300_vdaf269-B94","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10880-018-9584-5","article-title":"Lifespan development: symptoms experienced by individuals with neurofibromatosis type 1 associated plexiform neurofibromas from childhood into adulthood","volume":"26","author":"Jensen","year":"2019","journal-title":"J Clin Psychol Med Settings"},{"key":"2026042204272754300_vdaf269-B95","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1212\/WNL.0000000000201535","article-title":"Ten-year follow-up of internal neurofibroma growth behavior in adult patients with neurofibromatosis type 1 using whole-body MRI","volume":"100","author":"Ly","year":"2023","journal-title":"Neurology"},{"key":"2026042204272754300_vdaf269-B96","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40268-018-0248-6","article-title":"Treatment of disfiguring cutaneous lesions in neurofibromatosis-1 with everolimus: a phase II, open-label, single-arm trial","volume":"18","author":"Slopis","year":"2018","journal-title":"Drugs R D"},{"key":"2026042204272754300_vdaf269-B97","first-page":"vdaa095","article-title":"The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas","volume":"2","author":"Jackson","year":"2020","journal-title":"Neurooncol Adv"},{"key":"2026042204272754300_vdaf269-B98","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1212\/WNL.0000000000012437","article-title":"Imaging evaluation of plexiform neurofibromas in neurofibromatosis type 1: a survey-based assessment","volume":"97","author":"Ahlawat","year":"2021","journal-title":"Neurology"},{"key":"2026042204272754300_vdaf269-B99","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10072-021-05361-5","article-title":"Epidemiological and clinical burden associated with plexiform neurofibromas in pediatric neurofibromatosis type-1 (NF-1): a systematic literature review","volume":"43","author":"Iheanacho","year":"2022","journal-title":"Neurol Sci"},{"key":"2026042204272754300_vdaf269-B100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1212\/01.wnl.0000250332.89420.e6","article-title":"NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight","volume":"68","author":"Dombi","year":"2007","journal-title":"Neurology"},{"key":"2026042204272754300_vdaf269-B101","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"Prada","year":"2012","journal-title":"J Pediatr"},{"key":"2026042204272754300_vdaf269-B102","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","article-title":"Prognostic signs in the surgical management of plexiform neurofibroma: the Children\u2019s Hospital of Philadelphia experience, 1974\u20131994","volume":"131","author":"Needle","year":"1997","journal-title":"J Pediatr"},{"key":"2026042204272754300_vdaf269-B103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/B978-0-444-62702-5.00004-4","article-title":"Neurofibromatosis type 1","volume":"132","author":"Anderson","year":"2015","journal-title":"Handb Clin Neurol"},{"key":"2026042204272754300_vdaf269-B104","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/320121","article-title":"Mortality in neurofibromatosis 1: an analysis using US death certificates","volume":"68","author":"Rasmussen","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2026042204272754300_vdaf269-B105","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","article-title":"Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989","volume":"19","author":"Evans","year":"2011","journal-title":"Eur J Hum Genet"},{"key":"2026042204272754300_vdaf269-B106","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.0000000000002927","article-title":"Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials","volume":"87","author":"Wolters","year":"2016","journal-title":"Neurology"},{"key":"2026042204272754300_vdaf269-B107","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-3999(99)00004-5","article-title":"Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D)","volume":"46","author":"Hann","year":"1999","journal-title":"J Psychosom Res"},{"key":"2026042204272754300_vdaf269-B108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0005-7967(94)90078-7","article-title":"Detecting depression in chronic pain patients: adequacy of self-reports","volume":"32","author":"Turk","year":"1994","journal-title":"Behav Res Ther"},{"key":"2026042204272754300_vdaf269-B109","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s41687-025-00877-2","article-title":"Development of patient reported outcome measures assessing tumor pain intensity and tumor pain interference for individuals with neurofibromatosis type 1 and plexiform neurofibromas: qualitative findings","volume":"9","author":"Al Ghriwati","year":"2025","journal-title":"J Patient Rep Outcomes"},{"key":"2026042204272754300_vdaf269-B110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-7525-11-21","article-title":"Development of the adult PedsQL neurofibromatosis type 1 module: initial feasibility, reliability and validity","volume":"11","author":"Nutakki","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"2026042204272754300_vdaf269-B111","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1212\/WNL.0000000000012421","article-title":"Current recommendations for patient-reported outcome measures assessing domains of quality of life in neurofibromatosis clinical trials","volume":"97","author":"Wolters","year":"2021","journal-title":"Neurology"},{"key":"2026042204272754300_vdaf269-B112","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00381-022-05513-8","article-title":"Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA","volume":"38","author":"Yang","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"2026042204272754300_vdaf269-B113","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12883-023-03429-7","article-title":"Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey","volume":"23","author":"Yoo","year":"2023","journal-title":"BMC Neurol"},{"key":"2026042204272754300_vdaf269-B114","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40120-022-00365-5","article-title":"Burden among caregivers of pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States: a cross-sectional study","volume":"11","author":"Yang","year":"2022","journal-title":"Neurol Ther"},{"key":"2026042204272754300_vdaf269-B115","author":"Lawrence","year":"2021"},{"key":"2026042204272754300_vdaf269-B116","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/j.pain.0000000000001486","article-title":"Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment","volume":"160","author":"Bellampalli","year":"2019","journal-title":"Pain"},{"key":"2026042204272754300_vdaf269-B117","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"key":"2026042204272754300_vdaf269-B118","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdaf269\/66425071\/vdaf269.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdaf269\/68133324\/vdaf269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/8\/1\/vdaf269\/68133324\/vdaf269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:27:56Z","timestamp":1776846476000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdaf269\/8426827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,12]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdaf269","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"vdaf269"}}